NCT01879163View on ClinicalTrials.gov

Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Tuberculosis (TB)
Interventions
BIOLOGICAL

MVA85A-IMX313

Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)

BIOLOGICAL

MVA85A

Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)

Trial Locations (2)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford

B15 2TH

Wellcome Trust Clinical Research Facility, Birmingham

Sponsors

Collaborators (1)

Imaxio
All Listed Sponsors
collaborator

Imaxio

INDUSTRY

lead

University of Oxford

OTHER